Rapid Micro Biosystems to Exhibit at the 2023 PDA Pharmaceutical Microbiology Conference from October 2 – 4
September 29 2023 - 9:25AM
Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an
innovative life sciences technology company providing mission
critical automation solutions to facilitate the efficient
manufacturing and fast, safe release of healthcare products, today
announced its participation as a platinum sponsor and exhibitor at
the 2023 Parenteral Drug Association (“PDA”) Pharmaceutical
Microbiology Conference from October 2 - 4 in Washington, D.C.
This year’s conference will continue the ongoing tradition of
addressing the opportunities and challenges most relevant to the
future of pharmaceutical microbiology. Attendees will include
global microbiology and QA/QC process professionals, regulators,
academia and pharmaceutical industry consultants.
“We are proud to continue our Platinum Sponsorship of the 2023
PDA Pharmaceutical Microbiology Conference,” said Robert Spignesi,
President and CEO of Rapid Micro Biosystems®. “This conference is
the ideal setting for us to demonstrate how the Growth Direct®
System can help global pharmaceutical manufacturers meet both
today’s microbiological quality control standards and tomorrow’s
challenges. The Growth Direct is the only fully automated,
non-destructive growth-based platform for quality control
microbiology testing that offers faster time to results, improved
data integrity, enhanced accuracy, with greater sample
capacity.”
Rapid Micro’s booth will showcase the benefits of automating
microbial quality control with the Growth Direct® System’s software
and technology for rapid incubation, detection, and enumeration.
Other highlights of the conference will include:
- “Case Studies Applying Enhanced
Automation and Rapid Detection of Mold and Bacteria”, a poster
presentation by Danielle DeCesaro, MBA, Rapid Micro
Biosystems;
- “The Impact of Plate Size on Passive
Air Monitoring”, a poster presentation by Eric K. Chenelle, Rapid
Micro Biosystems; and
- “To Stress or Not to Stress”, a
poster presentation by Juan P. Rodriguez, MSc, Rapid Micro
Biosystems.
Investors and other parties interested in attending in person
are invited to register at: PDA Microbiology Conference 2023
About Rapid Micro Biosystems
Rapid Micro Biosystems is an innovative life sciences technology
company providing mission critical automation solutions to
facilitate the efficient manufacturing and fast, safe release of
healthcare products such as biologics, vaccines, cell and gene
therapies, and sterile injectables. The Company’s flagship Growth
Direct System automates and modernizes the antiquated, manual
microbial quality control (“MQC”) testing workflows used in the
largest and most complex pharmaceutical manufacturing operations
across the globe. The Growth Direct System brings the quality
control lab to the manufacturing floor, unlocking the power of MQC
automation to deliver the faster results, greater accuracy,
increased operational efficiency, better compliance with data
integrity regulations, and quicker decision making that customers
rely on to ensure safe and consistent supply of important
healthcare products. The Company is headquartered and has U.S.
manufacturing in Lowell, Massachusetts, with global locations in
Lexington, Massachusetts, Switzerland, Germany, and the
Netherlands. For more information, please
visit www.rapidmicrobio.com or follow the Company on
Twitter at @rapidmicrobio or on LinkedIn.
Investor Contact:
Michael Beaulieu, CFA
Vice President, Investor Relations and Corporate Communications
investors@rapidmicrobio.com
Media Contact:
media@rapidmicrobio.com
Rapid Micro Biosystems (NASDAQ:RPID)
Historical Stock Chart
From Sep 2024 to Oct 2024
Rapid Micro Biosystems (NASDAQ:RPID)
Historical Stock Chart
From Oct 2023 to Oct 2024